SEC Form 4 · accession 0001445064-16-000231
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nancy Lurker
Director
Period of report
Mar 16, 2016
Accepted (ET)
Mar 18, 2016 · 4:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Mar 16, 2016 | A | 4,041 | $0.00 | A | 10,965 | D | |
| Ordinary Shares | Mar 16, 2016 | F | 458 | $55.69 | D | 10,507 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Consists of restricted stock units that vest in their entirety as of the earlier of (a) March 16, 2017 or (b) the date of the Company's 2017 Annual General Meeting. The restricted stock units settle in ordinary shares upon vesting.